These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
559 related articles for article (PubMed ID: 27595142)
1. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Williams JG; Alam MF; Alrubaiy L; Arnott I; Clement C; Cohen D; Gordon JN; Hawthorne AB; Hilton M; Hutchings HA; Jawhari AU; Longo M; Mansfield J; Morgan JM; Rapport F; Seagrove AC; Sebastian S; Shaw I; Travis SP; Watkins A Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):15-24. PubMed ID: 27595142 [TBL] [Abstract][Full Text] [Related]
2. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT). Williams JG; Alam MF; Alrubaiy L; Clement C; Cohen D; Grey M; Hilton M; Hutchings HA; Longo M; Morgan JM; Rapport FL; Seagrove AC; Watkins A Health Technol Assess; 2016 Jun; 20(44):1-320. PubMed ID: 27329657 [TBL] [Abstract][Full Text] [Related]
3. Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT). Seagrove AC; Alam MF; Alrubaiy L; Cheung WY; Clement C; Cohen D; Grey M; Hilton M; Hutchings H; Morgan J; Rapport F; Roberts SE; Russell D; Russell I; Thomas L; Thorne K; Watkins A; Williams JG BMJ Open; 2014 Apr; 4(4):e005091. PubMed ID: 24785401 [TBL] [Abstract][Full Text] [Related]
4. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Laharie D; Bourreille A; Branche J; Allez M; Bouhnik Y; Filippi J; Zerbib F; Savoye G; Nachury M; Moreau J; Delchier JC; Cosnes J; Ricart E; Dewit O; Lopez-Sanroman A; Dupas JL; Carbonnel F; Bommelaer G; Coffin B; Roblin X; Van Assche G; Esteve M; Färkkilä M; Gisbert JP; Marteau P; Nahon S; de Vos M; Franchimont D; Mary JY; Colombel JF; Lémann M; Lancet; 2012 Dec; 380(9857):1909-15. PubMed ID: 23063316 [TBL] [Abstract][Full Text] [Related]
5. Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trial. Alam MF; Longo M; Cohen D; Groves S; Alrubaiy L; Hutchings HA; Watkins A; Sebastain S; Williams JG BMC Health Serv Res; 2023 Mar; 23(1):226. PubMed ID: 36890533 [TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Laharie D; Bourreille A; Branche J; Allez M; Bouhnik Y; Filippi J; Zerbib F; Savoye G; Vuitton L; Moreau J; Amiot A; Cosnes J; Ricart E; Dewit O; Lopez-Sanroman A; Fumery M; Carbonnel F; Bommelaer G; Coffin B; Roblin X; van Assche G; Esteve M; Farkkila M; Gisbert JP; Marteau P; Nahon S; de Vos M; Lambert J; Mary JY; Louis E; Gut; 2018 Feb; 67(2):237-243. PubMed ID: 28053054 [TBL] [Abstract][Full Text] [Related]
7. Healthcare professionals' views of the use and administration of two salvage therapy drugs for acute ulcerative colitis: a nested qualitative study within the CONSTRUCT trial. Clement C; Rapport F; Seagrove A; Alrubaiy L; Williams J BMJ Open; 2017 Feb; 7(2):e014512. PubMed ID: 28399515 [TBL] [Abstract][Full Text] [Related]
8. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. Choy MC; Li Wai Suen CFD; Con D; Boyd K; Pena R; Burrell K; Rosella O; Proud D; Brouwer R; Gorelik A; Liew D; Connell WR; Wright EK; Taylor KM; Pudipeddi A; Sawers M; Christensen B; Ng W; Begun J; Radford-Smith G; Garg M; Martin N; van Langenberg DR; Ding NS; Beswick L; Leong RW; Sparrow MP; De Cruz P Lancet Gastroenterol Hepatol; 2024 Nov; 9(11):981-996. PubMed ID: 39236736 [TBL] [Abstract][Full Text] [Related]
9. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Croft A; Walsh A; Doecke J; Cooley R; Howlett M; Radford-Smith G Aliment Pharmacol Ther; 2013 Aug; 38(3):294-302. PubMed ID: 23786158 [TBL] [Abstract][Full Text] [Related]
10. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. Chaparro M; Burgueño P; Iglesias E; Panés J; Muñoz F; Bastida G; Castro L; Jiménez C; Mendoza JL; Barreiro-de Acosta M; Senent SG; Gomollón F; Calvet X; García-Planella E; Gómez M; Hernández V; Hinojosa J; Mañosa M; Nyssen OP; Gisbert JP Aliment Pharmacol Ther; 2012 Jan; 35(2):275-83. PubMed ID: 22142227 [TBL] [Abstract][Full Text] [Related]
11. Infliximab for the treatment of acute exacerbations of ulcerative colitis. Bryan S; Andronis L; Hyde C; Connock M; Fry-Smith A; Wang D Health Technol Assess; 2010 May; 14 Suppl 1():9-15. PubMed ID: 20507798 [TBL] [Abstract][Full Text] [Related]
12. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. Weisshof R; Ollech JE; El Jurdi K; Yvellez OV; Cohen RD; Sakuraba A; Dalal S; Pekow J; Rubin DT J Crohns Colitis; 2019 Sep; 13(9):1105-1110. PubMed ID: 30726894 [TBL] [Abstract][Full Text] [Related]
13. Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. Corte C; Fernandopulle N; Catuneanu AM; Burger D; Cesarini M; White L; Keshav S; Travis S J Crohns Colitis; 2015 May; 9(5):376-81. PubMed ID: 25770163 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. Punekar YS; Hawkins N Eur J Health Econ; 2010 Feb; 11(1):67-76. PubMed ID: 19844750 [TBL] [Abstract][Full Text] [Related]
15. Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin: a systematic literature review. Thorne K; Alrubaiy L; Akbari A; Samuel DG; Morrison-Rees S; Roberts SE Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):369-82. PubMed ID: 26825217 [TBL] [Abstract][Full Text] [Related]
16. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S; Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038 [TBL] [Abstract][Full Text] [Related]
17. Patient views about the impact of ulcerative colitis and its management with drug treatment and surgery: a nested qualitative study within the CONSTRUCT trial. Rapport F; Clement C; Seagrove AC; Alrubaiy L; Hutchings HA; Williams JG BMC Gastroenterol; 2019 Oct; 19(1):166. PubMed ID: 31615445 [TBL] [Abstract][Full Text] [Related]
18. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial. Ponsioen CY; de Groof EJ; Eshuis EJ; Gardenbroek TJ; Bossuyt PMM; Hart A; Warusavitarne J; Buskens CJ; van Bodegraven AA; Brink MA; Consten ECJ; van Wagensveld BA; Rijk MCM; Crolla RMPH; Noomen CG; Houdijk APJ; Mallant RC; Boom M; Marsman WA; Stockmann HB; Mol B; de Groof AJ; Stokkers PC; D'Haens GR; Bemelman WA; Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):785-792. PubMed ID: 28838644 [TBL] [Abstract][Full Text] [Related]
19. Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis. Barberio B; Black CJ; Savarino EV; Ford AC J Crohns Colitis; 2021 May; 15(5):733-741. PubMed ID: 33175102 [TBL] [Abstract][Full Text] [Related]
20. Cyclosporine A for induction of remission in severe ulcerative colitis. Shibolet O; Regushevskaya E; Brezis M; Soares-Weiser K Cochrane Database Syst Rev; 2005 Jan; (1):CD004277. PubMed ID: 15674937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]